OpenEvidence Secures $1 Billion Valuation, Poised to Transform Global Healthcare

OpenEvidence, the AI-powered clinical decision-support platform for doctors, has secured a $1 billion valuation in a Sequoia Capital-led Series A funding round. This marks the company’s first institutional investment, bringing its total capital raised to over $100 million.

With this funding, OpenEvidence is set to scale its AI-driven medical knowledge platform, making critical, evidence-based insights more accessible to healthcare providers.

Revolutionizing Medical Knowledge with AI

OpenEvidence is changing how doctors access and apply medical knowledge, providing real-time AI-powered assistance at the point of care.

✅ Trusted by doctors – Used daily by hundreds of thousands of verified physicians across 10,000+ healthcare centers in the U.S.
✅ AI-powered insights – Helps doctors make informed clinical decisions in seconds
✅ Exclusive for medical professionals – Free for verified doctors in the U.S.
✅ Built for doctors, by AI experts – Developed by AI scientists from Harvard and MIT

"As we approach our platform’s two-year anniversary, OpenEvidence is already an essential tool for doctors. With this Series A from Sequoia, we’re just getting started." — Daniel Nadler, Founder of OpenEvidence

Next-Generation AI for Medical Decision-Making

A key focus of this funding round is advancing OpenEvidence’s medical AI models.

What’s Next?

🔹 Developing specialized Large Language Models (LLMs) for medicine
🔹 Expanding the AI team with top researchers in oncology, neuroscience, and cardiology
🔹 Scaling AI training to ensure more accurate, real-time insights

"Doctors are overwhelmed with growing caseloads and an explosion of medical knowledge. OpenEvidence is the solution they’ve been waiting for." — Pat Grady, Partner at Sequoia Capital

Strategic Partnership with the New England Journal of Medicine (NEJM)

As part of its expansion, OpenEvidence has announced a multi-year content partnership with NEJM Group, publisher of the New England Journal of Medicine (NEJM).

🔹 Access to 30+ years of trusted medical content from NEJM and its affiliated journals
🔹 Integrating peer-reviewed research to enhance AI-generated clinical answers
🔹 Empowering doctors with authoritative knowledge for better patient care

"Ensuring clinicians have access to trusted evidence is crucial. We’re excited to collaborate with OpenEvidence in this mission." — David Sampson, VP & Chief Publishing Officer, NEJM Group

The Future Potential of OpenEvidence in Global Healthcare

As OpenEvidence continues to grow, its potential impact on global healthcare is enormous.

How Scaling OpenEvidence Can Change the World:

🌎 Closing healthcare gaps – Bringing AI-powered decision support to rural and underserved areas
🔬 Accelerating medical research – AI-driven insights could help identify new treatments and optimize clinical trials
⚕️ Improving patient safety – Reducing misdiagnoses by providing real-time, evidence-based guidance
🦠 Predicting health trends – AI could help identify disease outbreaks before they spread

🔹 With medical knowledge doubling every 73 days, OpenEvidence ensures doctors stay up to date and deliver the best possible patient care.